Micro Lab Gets CDSCO panel Nod To Manufacture and Market Ebastine plus Phenylephrine FDC
New Delhi: Micro Labs has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and market the pulmonary fixed-dose combination (FDC) Ebastine plus Phenylephrine Hydrochloride Tablet.
This came after the firm presented its proposal and the bioequivalence (BE) report before the committee. The committee noted that CDSCO has already issued NOC for the proposed fixed-dose combination (FDC) on 04.01.2022 under an 18-month policy decision.
Ebastine plus Phenylephrine is used in the treatment of sneezing and runny nose due to allergies.
Ebastine belongs to the class of antihistamines (anti-allergic drugs) that work by blocking the action of histamine, a substance responsible for causing allergic reactions. It helps relieve allergy symptoms such as sneezing, running nose, watery eyes, itching, swelling, congestion, or stiffness.
Ebastine is used in the treatment of allergic conditions. Ebastine is an antihistaminic medication. It treats allergy symptoms such as itching, swelling, and rashes by blocking the effects of a chemical messenger (histamine) in the body. Your doctor has prescribed Ebastine to help relieve allergy symptoms such as itching, swelling, and rashes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.